OnCo
companiesCompany

Natera

Natera makes Signatera, the dominant tumour-informed MRD test.

Signatera (>1M tests; used in IMvigor011 leading to the first ctDNA-guided approval), Altera, Prospera (transplant), Panorama (prenatal).

Headquarters
Austin, TX, US
Type
diagnostics · NTRA

Products

1top
EstablishedTumour-informed ctDNA MRD test
Signatera

The most widely used blood test for detecting leftover cancer after surgery, personalised to each patient's tumour mutations.

Connected

14top

cancers

1
Colorectal cancer

fronts

1
Diagnostics & Biomarkers

technologies

3
Continuous and near-continuous ctDNA monitoringLiquid biopsy (ctDNA)MRD / molecular residual disease testing

drugs

1
EstablishedTumour-informed ctDNA MRD test
Signatera

ideas

5
An annual blinded shoot-out for liquid biopsy testsCertified reference samples to benchmark every tumour-DNA blood testKill combination arms early using circulating tumour DNA, before waiting for scansReference materials and open proficiency testing for residual disease testsUse tumour DNA in blood to decide when to pause treatment in metastatic cancer

bottlenecks

3
Dormant cells and minimal residual diseaseInherited risk is mostly unidentifiedTumour heterogeneity and clonal evolution